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Abstract
Background: Hearing loss increases the risk of poor outcomes across a range of life domains. Where hearing loss is
severe or profound, audiological interventions and rehabilitation have limited impact. Hearing dogs offer an
alternative, or additional, intervention. They live permanently with recipients, providing sound support and
companionship.
Methods: A single-centre, randomised controlled trial (RCT) evaluated the impacts of a hearing dog on mental
well-being, anxiety, depression, problems associated with hearing loss (responding to sounds, fearfulness/social
isolation), and perceived dependency on others. Participants were applicants to the UK charity ‘Hearing Dogs for
Deaf People’. Eligibility criteria were as follows: first-time applicant; applying for a hearing dog (as opposed to other
support provided by the charity). Participants were randomised 1:1 to the following: receive a hearing dog sooner
than usual [HD], or within the usual application timeframe (wait-list [WL] comparator). The primary outcome was
mental well-being (Short Warwick-Edinburgh Mental Well-Being Scale) 6 months (T1) after HD received a hearing
dog. The cost-effectiveness analysis took a health and social care perspective.
Results: In total, 165 participants were randomised (HD n = 83, WL n = 82). A total of 112 (67.9%) were included in
the primary analysis (HD n = 55, WL n = 57). At T1, mental well-being was significantly higher in the HD arm
(adjusted mean difference 2.53, 95% CI 1.27 to 3.79, p < 0.001). Significant improvements in anxiety, depression,
functioning, fearfulness/social isolation, and perceived dependency, favouring the HD arm, were also observed. On
average, HD participants had used fewer statutory health and social care resources. In a scenario whereby costs of
provision were borne by the public sector, hearing dogs do not appear to be value for money. If the public sector
made a partial contribution, it is possible that hearing dogs would be cost-effective from a public sector
perspective.
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Conclusions: Hearing dogs appear to benefit recipients across a number of life domains, at least in the short term.
Within the current funding model (costs entirely borne by the charity), hearing dogs are cost-effective from the
public sector perspective. Whilst it would not be cost-effective to fully fund the provision of hearing dogs by the
public sector, a partial contribution could be explored.
Trial registration: The trial was retrospectively registered with the International Standard Randomised Controlled
Trial Number (ISRCTN) registry on 28.1.2019: ISRCTN36452009.
Background
One in twenty of the world’s population currently live
with a hearing loss which impacts their everyday lives.
This figure is projected to double by 2050 as the world
population ages [1]. Prevalence varies between countries,
likely due to differences in age demographics [2]. In the
United Kingdom (UK), one in six adults have hearing
loss and around one in a hundred are severely or pro-
foundly deaf [3]. Hearing loss, particularly acquired
hearing loss in adulthood, is associated with increased
risk of poorer quality of life and negative impacts on
many life domains including social networks and social
inclusion, work and mental and physical health [4–9].
Hearing loss is also associated with cognitive decline and
increased risk of dementia [10, 11]. The severity of hear-
ing loss increases the risk for, and severity of, negative
impacts on people’s lives.
For those with severe or profound hearing loss, hear-
ing aids offer little benefit [3]. Cochlear implants may be
an option for some individuals and are likely to yield
greater benefit than hearing aids, particularly in terms of
supporting one-to-one communication. However, they
can only partially ameliorate the impact of hearing loss
on managing and participating in everyday life [12, 13].
Where people are unable to benefit, or achieve limited
benefit, from audiological interventions, the focus shifts
to adaptation to hearing loss and the prevention (or
minimisation) of adverse outcomes [3]. Rehabilitation in-
terventions, addressing speech perception/communica-
tion skills, functional adaptation (including equipment
provision) and emotional support needs, may be avail-
able. However, these are short term and typically pro-
vided soon after experiencing a significant deterioration
in hearing. Overall, evidence on their effectiveness is
poor quality and equivocal, particularly in terms of sus-
tained benefit [14–16].
A further, or alternative, type of rehabilitative inter-
vention is to acquire a hearing dog. Hearing dogs are an-
imals specifically trained to provide ‘sound support’; that
is, the ability to respond to common ‘daily living’ sounds
(e.g. doorbell, fire alarm, family member calling name)
and to use different behaviours to alert and identify the
sound to the deaf individual. Similar to other assistance
dogs (e.g. guide dogs), there are accredited charities
providing hearing dogs in many European countries,
North America, Australia and New Zealand. Accredited
hearing dog providers adhere to international standards
for the assistance dog industry related to dog training
and assessment, supporting the ‘hearing dog partner-
ship’, and dog welfare [17]. Whilst ownership is retained
by the hearing dog provider, the dog lives permanently
with the recipient becoming, as a result, a companion as
well as providing sound support [18]. As with other as-
sistance dogs, hearing dogs are (though varying in de-
gree between countries) legally entitled to access public,
workplace and commercial/business spaces which typic-
ally prohibit pet dogs [19]. Hearing dog recipients are
encouraged to take their hearing dog with them when-
ever they leave their home. On these occasions, the dog
wears a jacket that clearly conveys it is a working dog
supporting someone with hearing loss. The hearing dog
partnership is supported by the provider via on-going,
individualised support.
Existing research evidence [20–26] on the impacts
of hearing dogs on people’s lives is limited and study
designs preclude robust conclusions being drawn.
However, they do indicate that hearing dogs may have
the potential to affect a range of outcomes. That
hearing loss increases the risk for poorer outcomes
across a wide range of life domains (and resultant de-
mands on public sector services), and the fact that
audiological and rehabilitation interventions appear to
have limited impact, make a strong case to investigate
the effectiveness and cost-effectiveness of hearing
dogs. In terms of economic evaluations, Lundqvist
et al. [27] recently undertook a cost-effectiveness ana-
lysis of ‘certified service dogs’. However, this did not
include study participants (n = 3) with hearing dogs
included in the effectiveness study [28].
Internationally, the number of, and demand for, hear-
ing and other assistance dogs is increasing [25, 29]. Cur-
rently, such interventions are outwith [21] statutory
support with the public via charitable donations (or in
some countries, individuals) funding this provision.
However, the trend in some countries towards offering
individuals the option of holding a budget with which to
manage their health/social care arrangements opens up
the possibility of the state (indirectly) contributing to
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such interventions, if only in allowing their use to sup-
port the dog’s living costs. Health and social work/care
professionals therefore need robust evidence on which
to provide information and advice to people with hear-
ing loss. Individuals with hearing loss also need access to
high-quality evidence to support decision-making. Hav-
ing a hearing dog is not an insignificant decision; hear-
ing dog partnerships typically last around 10 years,
added to that are the impacts on daily routines and fam-
ily life that come with having a dog in the household.
This paper reports on a pragmatic, randomised con-
trolled trial which sought to evaluate the impact of a
hearing dog on the lives of recipients compared to those
not yet in receipt of a hearing dog. The trial included a
nested economic evaluation. The setting for the study
was Hearing Dogs for Deaf People [30], the only organ-
isation accredited to provide hearing dogs to UK resi-
dents [17]. Study objectives were as follows:
 To determine the impact of a hearing dog
partnership on mental well-being 6 months post-
receipt of a hearing dog, compared with individuals
who have not yet received their hearing dog.
 To determine the impact of a hearing dog
partnership on secondary outcomes of impairment
in anxiety, depression, functioning and hearing loss-
associated difficulties 6 months post-receipt of a
hearing dog.
 To conduct a nested economic evaluation to
investigate the cost-effectiveness of hearing dogs.
The study protocol has been published [31] and this
includes details of other elements of the research, in-
cluding collecting initial, exploratory data on longer-
term outcomes and a nested, longitudinal qualitative
study. Findings from these will be published elsewhere.
As well as being the first RCT to evaluate hearing dogs,
it is also only the second randomised trial within the
wider field of research on assistance dogs for sensory or
motor impairments, the other one being a trial in the




We conducted a single-centre, superiority, randomised
controlled trial (RCT) using a 1-1 allocation ratio and
with a nested economic evaluation. Full study details are
described in the protocol [31] and a CONSORT check-
list is available (Additional file 1). The trial was regis-
tered retrospectively (ISRCTN36452009). The protocol
omitted in error to state that outcomes data collection
included a single item question on perceived dependency
on others. There are no other changes to the published
protocol. The trial took place between March 2017 and
January 2020.
Intervention
The study concerned hearing dogs bred and trained by
Hear ing Dogs for Deaf People (HDfDP) (www.
hearingdogs.org.uk), the UK’s only accredited hearing
dog provider [17].
The intervention was receipt of a hearing dog. The
comparator was no hearing dog (using a wait-list de-
sign). An overview of HDFDP’s breeding and training
programmes, and the process by which a hearing dog is
matched to and placed with an applicant to HDfDP are
outlined below. Further information can be obtained
from HDfDP.
HDfDP’s breeding and training programmes
HDfDP only works with the following dog breeds: labra-
dor retriever, cocker spaniel, miniature poodle and
mixed breed cockapoos and has its own puppy breeding
programme. Brood bitches live with volunteers in regu-
lar households [33], and this is where puppies spend
their first 8 weeks, with initial socialising work intro-
duced at 5 weeks [34]. At 8 weeks, puppies are placed
with a puppy training volunteer in a regular household,
living with the volunteer for around 16months. A four-
stage, rewards-based training programme [35] is imple-
mented by the volunteer during this period, with regular
supervision and support from HDfDP’s Puppy Training
Team. The standards required to progress through the
stages of training and be registered as hearing dog ad-
here to international standards for the assistance dog in-
dustry [17, 35]. Dogs are typically placed within a month
of passing hearing dog accreditation [36]. The following
section describes the application, matching and place-
ment process.
The application, matching and placement process
Individuals with severe or profound hearing loss are eli-
gible to apply to HDfDP for a hearing dog. HDfDP aim
to pair an applicant with a hearing dog within 2.5–3
years of their application. Medical evidence of severe or
profound hearing loss is required for an application to
be accepted. A detailed assessment process follows, typ-
ically taking 3 to 6 months, during which a profile of the
applicant is created. Dogs nearing end of their training
(at ~ 20 months old) are screened against these profiles
in order to identify potential applicant/hearing dog
‘matches’. A number of factors are taken into account
when identifying potential matches. These include any
preferences regarding breed and size of dog, applicant
and dog temperament, applicant life-style (e.g. sedentary
vs active) and household (e.g. presences of children or
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cats), location and the settings where the dog will work
(e.g. nature of workplace, use of public transport).
Once an applicant is matched with a specific dog, the
match is assessed over a 2-day, residential period. If suc-
cessful, the dog undergoes further training specific to
the settings in which they will be working (e.g. work or
travelling environment, idiosyncratic sounds) before per-
manent placement with the recipient. In the early days,
the placement is closely monitored and supported on a
needs basis by a HDfDP partnership instructor (PIs) via
home visits. During the first 12 months, this gradually
decreases in intensity. After that, PIs visit at least annu-
ally and can be contacted at any time by the hearing dog
recipient.
HDfDP need categorisation
The HDfDP assessment includes assigning an applicant
to one of four categories of need pertinent to matching
them with a hearing dog:
 No remarkable/particular needs,
 Predominantly personal needs (e.g. particular health
concerns, mobility issues),
 Predominantly environmental needs (e.g. inner city
location, cats in the home),
 Both personal and environmental needs.
Study participants
Participants were applicants to HDfDP. HDfDP opens
for applications four times a year (on-line or postal).
During each round, they receive in excess of 300 appli-
cations, of which around fifty are offered the opportunity
to progress their application (dependent on projected
volume of dogs nearing the end of training). HDfDP’s
criteria for accepting an application are as follows: indi-
vidual has severe or profound hearing loss (evidenced by
audiology report); is able to meet the welfare, physical
and training needs associated with having a hearing dog
(evidenced by a report from the applicant’s general prac-
titioner (GP)); and any dog in the household is 10 years
or older.
Trial inclusion criteria:
 Application for a hearing dog accepted by HDfDP
 First-time applicant to HDfDP
 Applying for a hearing dog
 Aged 18 or over.
Trial exclusion criteria:
 Applying for a dual assistance (sound and vision) or
companion dog
 Applying for a replacement hearing dog due to
impending retirement or death of/previous hearing
dog
 Presence of cognitive impairment (indicated by use
of proxy during application process).
Recruitment and baseline data collection
HDfDP screened all accepted applications between
March 2017 and March 2018 against study eligibility cri-
teria and posted a Study Recruitment Pack to those ful-
filling the criteria. Recruitment materials clearly stated
the research team was independent of HDfDP and no
data would be shared with the organisation. Individuals
deciding to join the study returned the consent form
and baseline questionnaire to the research team at the
University of York. Print versions of recruitment mate-
rials included details of how to access electronic versions
(English or British Sign Language [BSL]) hosted on the
Qualtrics© survey 7 (platform). Participants received a
£20 shopping voucher as a ‘thank you’ for returning
their baseline questionnaire.
Randomisation
As soon as the profiles of two participants with the same
HDfDP need categorisation were completed, pairwise
randomisation was used to allocate one each to receive a
hearing dog:
 Sooner than usual (hearing dog (HD) arm); or
 Within HDfDPs usual timeframe (wait-list (WL)
comparator arm)
Participants were blinded to their group allocation.
Randomisation was carried out by a trial statistician at
York Trials Unit using an allocation schedule generated
in Stata v15. Study team members who were actively in-
volved in the administration of the trial were not
blinded.
After randomisation, HD profiles were immediately
made available to HDfDP trainers to identity a suitable
hearing dog ‘match’. WL profiles were not made avail-
able until 6 months after HD received their dog or, to
fulfil HDfDP’s commitment to receive a hearing dog
within 2.5 to 3 years of applying, 16 months after ran-
domisation, whichever came first.
The study adhered to HDfDP protocols regarding ces-
sation of a hearing dog partnership. Cessation may be
instigated by the recipient (e.g. significant deterioration
in their health), the organisation (e.g. concerns about
dog welfare) or where recipient and the organisation
jointly decide that the match has not proved successful
(e.g. dog behaviour issues, mis-match in dog and recipi-
ent vitality).
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Pre-randomisation, participants who withdrew their
application for a hearing dog or had their application
closed by HDfDP (due to evidence emerging during the
assessment process that the participant did not meet
HDfDP acceptance criteria) were no longer eligible for
participation in the trial. Post-randomisation, all partici-
pants, regardless of their application or partnership sta-
tus remained within the trial unless they withdrew
consent. Where a HD participant withdrew their appli-
cation post-randomisation, the research team created a
dummy partnership date from which to trigger T1 data
collection. If HDfDP closed an application post-
randomisation or removed the hearing dog, they had the
option to request that the participant was removed from
the study.
Follow-up data collection
The first follow-up data collection (T1) for each rando-
mised pair took place 6 months after the HD participant
received a hearing dog, at which point the WL counter-
part was not expected to have received their dog. This
was the primary time point. The decision to use 6
months after receipt of hearing dog as the primary time
point was informed by two main considerations: (i) ad-
vice from HDfDP that, by that time, the settling in and
adjustment period has typically passed and the partner-
ship between individual and hearing dog well-
established; (ii) ensuring HDfDP would maintain its
commitment that all applicants (including those in the
WL group) receive a hearing dog within 2.5–3 years of
their application.
Follow-up data collection was administered by the re-
search team via post or email (containing link to elec-
tronic versions (English or BSL) of study questionnaire)
according to participants’ preferences. Email/post and
text reminders, and ‘thank you’ shopping vouchers (£20)
supported retention.
Outcome measures
The selection of outcome measures was informed by the
existing literature and in consultation with Hearing Dogs
for Deaf People and hearing dog recipients.
Primary outcome
Self-reported mental well-being was measured using
the 7-item Short Warwick-Edinburgh Mental Well-
being Scale (SWEMWBS) [37]. This is scored between
7 and 35 and can be classified to indicate low (7–
19.3), medium (19.4–28.0) and high (28.1–35) well-
being [38]. Internal reliability for the study sample
was excellent a = 0.90.
Secondary outcomes
Work and Social Adjustment Scale (WSAS) [39] mea-
sures perceived functional impairment associated with a
specified health problem/disability with respect to five
domains (work, home management, social leisure activ-
ities, private leisure activities and relationships with
others) each represented by a single item. It yields a
score between 0 and 40 (0–9 indicates low impairment,
10–19 moderate impairment, and 20–40 severe impair-
ment). Internal reliability for the study sample was good
a = 0.84.
Generalised Anxiety Disorder Assessment (GAD-7)
[40] is a seven-item instrument measuring anxiety. A
4-point rating scale (0–3) for each item yields a total
score between 0 and 21 (0–4 indicates minimal anx-
iety, 5–9 mild, 10–14 moderate, and 15–21 severe).
Internal reliability for the study sample was excellent
a = 0.93.
Patient Health Questionnaire (PHQ-9) [41] is a
nine-item instrument measuring depression. A 4-point
rating scale (0–3) for each item yields a total score
between 0 and 27 (0–4 indicates no depression, 5–9
mild, 10–14 moderate, 15–19 moderately severe, and
20–27 severe). Internal reliability for the study sample
was excellent a = 0.91.
Hearing Loss Questionnaire (HLQ) comprises two sub-
scales (HLQ-Sound (6 items), HLQ-Social (5 items))
which capture frequency of exposure to problems deaf
people report experiencing in everyday life using a five-
point rating scale (1 = never to 5 = almost always).
HLQ-Sound is scored 6–30 and concerns problems with
sound detection/identification. HLQ-Social is scored 5–
25 and concerns problems with feeling safe, dependence
on others and social avoidance. The HLQ was derived
from a checklist developed by a previous hearing dog
evaluation [22] and which analysed items individually.
To determine whether we could treat it as a scale, we
analysed baseline data using a classical test theory ap-
proach [42]. Tests of face validity and exploratory factor
analysis indicated a two-factor structure capturing (i)
problems with responding to environmental sounds and
dependency on others to act as ‘ears’ (HLQ-Sound), and
(ii) fearfulness and social isolation (HLQ-Social). Tests
of reliability (alpha co-efficients: HLQ-Sound a = .82,
HLQ-Social a = .85) indicated it was appropriate to use
subscale scores. Split-half and test-retest reliability were
also acceptable. (Further information available from
authors).
Perceived dependency is a single question assessed per-
ceived dependency on others: In a typical week, on how
many days do you need family or friends to help you
overcome any difficulties caused by hearing loss?
Validated BSL versions of the SWEMWBS, GAD-7,
PHQ-9 and WSAS were already available [43, 44]. The
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research team created a BSL version of the HLQ and
perceived dependency question.
Compliance
HDfDP retained the right to allocate a hearing dog to a
WL participant before T1 should the applicant’s un-
usual/complex needs significantly reduce the number of
hearing dogs with the required specific aptitudes/skills
likely to become available within the 3 years HDfDP
commits to applicants receiving a hearing dog. Instances
were recorded by the study team.
Sample size
Recruitment was scheduled for a 12-month period dur-
ing which we estimated that 200 individuals would be
approached to take part and 180 would be eligible for
recruitment to the study. We assumed that approxi-
mately 90% would opt to join the trial (n = 162) and at
least 128 (80% of these) would be retained at T1. This
would result in 80% power to detect an effect size of 0.5
of a standard deviation in our primary outcome measure
(two-sided 5% alpha).
Statistical analysis
Full details of the statistical analysis plan are available
(ISRCTN36452009). Data were entered into SPSS Ver-
sion 26 by staff not involved in data analysis. A random
sample of 10% was double entered to assess data quality.
A 5% threshold for the error rate was set to trigger fur-
ther investigation but the error rate did not exceed this.
Management of missing data followed guidance from
scale developers where available. For the HLQ, we re-
placed up to one missing item in each subscale with the
subscale mean.
Baseline data were summarised descriptively by trial
arm as randomised and as included in the primary ana-
lysis. Analysis was conducted using two-sided statistical
tests at the 5% significance level using available case
intention-to-treat.
The primary analysis estimated the difference in
SWEMWBS scores at T1 between HD and WL using
linear regression adjusting for the baseline score and the
individual’s HDfDP need categorisation. Secondary out-
comes (WSAS, GAD-7, PHQ-9, HLQ, Perceived de-
pendency) were analysed in the same way.
Standardised effect sizes were calculated by dividing
the adjusted mean difference by the standard deviation
of the analysed sample at baseline. An effect size of 0.2
was described as a small effect size, 0.5 a medium effect
size and > 0.8 a large effect size [45].
Secondary analyses included a series of ordinal logistic
regressions, adjusting for HDfDP needs categorisation
and baseline scores, which compared differences
between arms at T1 in distribution across severity classi-
fications of the SWEMWBS, GAD7, PHQ-9 and WSAS.
A Complier Average Causal Effect (CACE) analysis
[46] was conducted for the primary outcome to estimate
the effect of receiving a hearing dog accounting for non-
compliance and contamination. A two-stage least
squares, instrumental variable (IV) approach was used,
adjusting for presenting needs and baseline value of the




The following was collected at baseline, randomisation
and T1:
 Health-related quality of life, measured using the
EuroQol 5 Dimensions (EQ-5D-5L [47]. This
profiles health-related quality of life (HRQoL) on the
dimensions of mobility, self-care, usual activities,
pain/discomfort and anxiety/depression and accord-
ing to 5 levels of severity (no problems to extreme
problems). For the UK, the crosswalk range of scores
is − 0.594 to 1 [48].
 A questionnaire developed specifically for the study,
and reflecting the specific needs of the population,
collected data on use of primary/community and
secondary health care and social care services in the
previous 3 months. (Questionnaire available from
the research team)
Analytical perspective
The cost-effectiveness analysis took a health and social
care perspective which asked, compared to usual care,
does providing hearing dogs provide value for money for
the National Health Service (NHS) and local authorities
(LA)? Or, in other words, does investing public sector
resources in hearing dogs generate more benefit than
could be generated by alternative spending? The main
analysis considered two separate scenarios:
1. The costs of providing hearing dogs is borne by the
charity (the current situation)
2. The public sector funds the cost of providing
hearing dogs.
Based on findings from the main analysis, a subse-
quent analysis considered how much the public sector
could contribute towards the cost of hearing dogs with
the expenditure representing value for money.
Data analysis
Health and social care services used by study partici-
pants were costed (see Additional file 2 for unit costs;
Stuttard et al. Trials          (2021) 22:700 Page 6 of 15
where possible these were based on national average
costs). The cost of providing hearing dogs (which in-
cludes breeding, puppy training, hearing dog training,
assessment and matching applicant to dog, and Partner-
ship Instructor support ) was calculated using HDfDP’s
2017/18 financial accounts. More detail on costs cannot
be reported in this paper due to commercial sensitivity.
However, these can be made available to research teams
on request.
EQ-5D-5L responses were converted onto the EQ-5D-
3L instrument using the crosswalk algorithm developed
by Van Hout et al. [49] to estimate HRQoL scores as
recommended by NICE [50]. Then, health quality-
adjusted life-years (H-QALYs) were calculated using the
area under the curve method [51]. H-QALYs are a gen-
eric measure of health which captures both quantity and
quality of life with one H-QALY representing a year
spent in perfect health. In addition, the HRQoL scores
were converted into the Adult Social Care Outcome
Toolkit (ASCOT) score using the exchange rate pro-
posed by Stevens et al. [52] ASCOT scores were used to
estimate social care-QALYs (SC-QALYs) using the area
under the curve method [51].
For each scenario, we conducted two analyses:
i. The whole trial period (baseline to T1)
ii. The active intervention period (receipt of hearing
dog to T1)
Table 1 provides more detail about these approaches.
Model selection was carried out using Akaike and
Bayesian information criterion (AIC and BIC). In the
whole trial period analysis, the difference in QALYs and
costs between the two arms of the trial were estimated
by ordinary least square (OLS). In the active intervention
period analysis, the difference in QALYs was estimated
using generalised linear model (GLM) with the log-link
and normal distribution. The difference in costs in the
scenario excluding the cost of the hearing dog was esti-
mated using GLM with log-link and gamma distribution.
The difference in costs in the scenario including the cost
of the hearing dog was estimated using OLS. QALY and
cost regressions included the EQ-5D-5L score and
health and social care costs in natural units at baseline,
respectively, in order to adjust for baseline differences
across participants. All regressions included three dum-
mies indicating the HDfPD’s ‘needs categorisation’ (the
reference category: no remarkable/particular needs). For
each time point, missing data were imputed using mul-
tiple imputation chain equation with predictive mean
matching [53].
Cost-effectiveness was calculated using the incremen-
tal cost-effectiveness ratio (ICER), which reports the in-
cremental cost per QALY gained of one intervention
compared to another. The incremental net health benefit
(NHB) for hearing dogs compared to standard care was
also estimated which captures the overall health gain
from one individual receiving a hearing dog. This meas-
ure reflects any health benefits to that individual, and
the impacts on other people’s health from any change in
resource requirements. If hearing dogs are cost saving,
those resources (or funds) can be used to generate add-
itional health for other individuals, resulting in further
health gain. In contrast, if they increase costs those re-
sources are not available for others, resulting in health
losses. Incremental net health benefit was estimated
using three different cost-effectiveness thresholds:
£15,000 [54], £20,000 and £30,000 per QALY [50]. Each
Table 1 Description of the whole trial period and the active intervention period: cost-effectiveness analysis
Whole trial period Active intervention period
Rationale To test whether, before receipt of a HD, the idea of receiving a HD
might have an impact on differential QALYs and costs.




From baseline to T1. This was calculated as 21months long. It is the
average duration between baseline and T1 minus 6 months when
the HD arm received a HD (i.e. approximately 15 months), plus 6
months of the active intervention.
From T1 minus 6 months when the HD arm received the HD,
to T1 at 6 months.
Assumptions QALYs:
• HRQoL remains the same from baseline to receipt of the HD by the
HD arm.
• HRQoL changes linearly from receipt of the HD in the HD arm to
T1.
Costs:
• Resource use in the 3 months prior to baseline is representative of
the resource use between baseline and the time in the HD arm to
receipt of a HD.
• Resource use in the 3 months prior to T1 is representative of the
entire 6-month active intervention period.
QALYs:
• HRQoL remains the same from randomisation to the HD arm
receiving the HD.
• HRQoL changes linearly from the HD arm receiving the HD to
T1.
Costs:
• Resource use in the 3 months prior to T1 is representative of
the 6-month active intervention period.
Limitations The calculation of QALYs and costs requires additional assumptions
which might not hold true in reality.
This analysis may not capture the differential QALYs and costs
potentially incurred had the HD arm been in receipt of a HD at
baseline.
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of the thresholds represents an estimate of the health
opportunity cost (i.e. the QALYs that could have been
generated elsewhere from the same resources). To esti-
mate how much the NHS could contribute towards
hearing dogs, the maximum price was estimated at
which the incremental NHB was still positive, that is
how much could be spent on hearing dogs before any
health gain generated from hearing dogs was exceeded




Figure 1 summarises the flow of participants through
the study. In total, 213 individuals were recruited to the
study of whom 165 (77%) were randomised (Fig. 1) (HD
n = 83, 50%; WL n = 82, 50%). A total of 112 rando-
mised participants (68%) were included in the primary
analysis; 51 (HD n = 24; WL n = 27) were not followed
up at T1 as this was not triggered within the study time-
frame (dictated by funding envelope), and two did not
provide valid SWEMWBS at baseline. Of those followed
up at T1 (and their data included in the analysis), 87% of
HD arm participants had received a hearing dog and
91% of WL arm participants were still waiting to receive
a hearing dog. Where T1 data collection was attempted,
the response rate was 93%.
Randomised sample: characteristics
Three quarters of the sample were female (n = 123) and
the average age was 48 years (range 18–86, Table 2). Just
under half (49%) were married or living as married, 44%
were single or divorced/separated, and 7% widowed.
Sixty percent reported having an additional long-term
condition (e.g. mental health, mobility, stamina/fatigue).
Duration of severe/profound hearing loss ranged from
1 to 76 years. In terms of HDfDP’s additional needs clas-
sification, 53% had no additional needs, 24% had pre-
dominantly environmental needs, 15% had
predominantly personal needs, and 8% both personal
and environmental needs.
Baseline characteristics were balanced between the
two arms as randomised and as analysed (see Table 2).
Comparison of the randomised sample with the study
population (aggregate data provided by HDfDP, data
available on request) indicated the study sample was rep-
resentative of current applicants.
Primary analysis
There was evidence of a difference in SWEMWBS score
at T1 (Table 3) favouring HD (adjusted mean difference
between arms 2.53, 95% CI 1.27 to 3.79, p < 0.001; effect
size 0.6).
Secondary outcomes
With respect to the secondary outcome measures, with
the exception of the HLQ-Sound, there was evidence of
a difference between the two groups at T1 favouring HD
(Table 3). Effect sizes were small (WSAS, PHQ-9, HLQ-
Sound, HLQ-Social) or medium (GAD-7, Perceived
dependency).
Fig. 1 CONSORT flow diagram: enrolment to T1
Stuttard et al. Trials          (2021) 22:700 Page 8 of 15
Further analyses
At T1, categorisation according to SWEMWBS clinical
severity classifications differed between HD and WL (see
Table 4). For HD, the odds of being categorised as high
well-being (versus medium/low well-being) were 4.20
(95% CI 1.76 to 10.05, p < 0.001) times those of WL.
Similar patterns were observed for the GAD-7 and
PHQ-9, but not the WSAS (Table 4).
Complier Average Causal Effect (CACE) analysis
Within the analysed sample, 87% (48/55) of HD arm
participants had a hearing dog and 91% (52/57) of WL
arm participants had not received a hearing dog at T1
(Fig. 1). The CACE estimate of the effect of receiving a
hearing dog was a difference in SWEMWBS score
favouring the HD arm of 3.19 (95% CI 1.65 to 4.73, p <
0.001, effect size 0.78).
Cost-effectiveness analysis
As for the effectiveness analysis, the analysed sample (n
= 165) comprised n = 83 (HD arm) and 82 (WL arm).
Table 5 shows descriptive statistics and results for the
cost-effectiveness analysis for the whole trial period and
the active intervention period. Additional file 3 presents,
Table 2 Baseline characteristics
As randomised Included in primary analysis (trial)
Hearing dog (n = 83) Wait-list (n = 82) Total (n = 165) Hearing dog (n = 55) Wait-list (n = 57) Total (n = 112)
Sex n (%)
Female 63 (75.9) 60 (73.2) 123 (74.5) 42 (76.4) 41 (71.9) 83 (73.1)





























White British 78 (94.0) 80 (97.6) 158 (95.7) 52 (94.5) 56 (98.2) 108 (96.4)
All other 5 (6.0) 2 (2.4) 4 (4.2) 3 (5.5) 1 (1.8) 4 (3.6)
Relationship status n (%)
Single 31 (37.3) 27 (32.9) 58 (35.2) 22 (40.0) 18 (31.6) 40 (35.7)
Married/cohabiting 39 (47.0) 39 (47.6) 78 (47.3) 27 (49.1) 28 (49.1) 55 (49.1)
Separated/divorced 10 (12.0) 11 (13.4) 21 (12.7) 3 (5.5) 6 (10.5) 9 (8.0)
Widowed 3 (3.6) 5 (6.1) 8 (4.8) 3 (5.5) 5 (8.8) 8 (7.1)
Long-term health conditions (expected to last more than 12months) n (%)
Yes 48 (57.8) 49 (59.8) 97 (58.8) 29 (52.7) 32 (56.1) 61 (54.5)
No 35 (42.2) 33 (40.2) 68 (41.2) 26 (47.3) 25 (43.9) 51 (45.5)
Prior pet dog experience n (%)
Yes 56 (67.5) 54 (65.9) 110 (66.7) 37 (67.3) 39 (68.4) 76 (67.9)
No 27 (32.5) 28 (34.1) 55 (33.3) 18 (32.7) 18 (31.6) 36 (32.1)














Median (range) 25 (1–76) 20 (2–76) 22 (1–76) 25 (1–63) 20 (2–76) 22 (1–76)
HDfDP needs categorisationc n (%)
None 43 (51.8) 44 (53.7) 82 (52.7) 28 (50.9) 31 (54.4) 59 (52.7)
Personal 12 (14.5) 13 (15.9) 25 (15.2) 6 (10.9) 5 (8.8) 11 (9.8)
Environmental 21 (25.3) 18 (22.0) 39 (23.6) 17 (30.9) 17 (29.8) 34 (30.4)
Both 7 (8.4) 7 (8.5) 14 (8.5) 4 (7.3) 4 (7.0) 8 (7.1)
aMissing data for 4 participants
bMissing data for 2 participants
c None no remarkable/particular needs, personal predominantly personal needs (e.g. particular health concerns, mobility issues), environmental predominantly
environmental needs (e.g. inner city location, cats in the home), both personal and environmental needs
Stuttard et al. Trials          (2021) 22:700 Page 9 of 15
for each time point, descriptive information on health
(Table 6) and social care resource use (Table 7), EQ-5D-
5L index score, health and social care costs (Table 8),
and missing data (Table 9).
For the whole trial period, on average, QALYs for the
HD arm were higher than for the WL arm (1.300 vs
1.256). The estimated differential QALY (δQALY) was
0.012 (ns). In the scenario where the cost of a hearing
dog is borne entirely by the charity, the estimated differ-
ential cost (δCOST) was − £260, indicating that public
sector care costs were lower for the HD arm. This differ-
ence was not statistically significant but, on average, it
was driven by 0.6 fewer other outpatient visits (statisti-
cally significant at the 1% level) and 0.2 fewer day cases
(statistically significant at the 10% level) in the HD arm.
When the cost of the hearing dog (£3,214 for the 6-
month active intervention period) was included, δCOST
was £2954 and was statistically significant, that is total
costs were, on average, higher in the HD arm. Discount-
ing QALYs and costs in the second year (from month 13
to 21) at 3.5%, in line with NICE guidance [55], had no
impact on the results.
Results for the active intervention period were similar
with a marginally higher estimated differential QALY
(δQALY) of 0.014, and marginally higher cost savings
(δCOST) of £291, indicating that public sector care costs
were lower for the HD arm. When the cost of the hear-
ing dog was included, δCOST was £2954 and was statisti-
cally significant. That is, total costs were, on average,
higher in the HD arm.
In the scenario where the cost of the hearing dogs are
fully borne by the charity, hearing dogs improved out-
comes and reduced costs and were therefore the domin-
ant, cost-effective strategy. In line with this finding,
NHB was positive for the whole trial and active interven-
tion period for all three cost-effectiveness thresholds (i.e.
£15,000, £20,000 and £30,000 per QALY). The probabil-
ity that the hearing dog was cost-effective was over 94%
for all health opportunity cost thresholds considered.
In contrast, in the scenario where the cost of a hearing
dog is fully borne by the public sector, the ICER was
£242,912 per QALY for the whole trial analysis period
and £203,959 per QALY for the active intervention
period. These values are considerably higher than the
highest threshold of £30,000 per QALY and indicate that
under this scenario, hearing dogs are not cost-effective.
This is confirmed by a probability of cost-effectiveness
equal to 0% and a negative NHB for all three thresholds.
Figure 4 (Additional file 4) provides graphical represen-
tation of these findings using the cost-effectiveness plane
Table 3 Linear regression analyses: primary and secondary outcomes





Baseline T1 Baseline T1
Short Warwick-Edinburgh Mental Well-being Scale
n 55 57 2.53 (1.27 to 3.79)
p < 0.001
0.60
Mean (SD) 21.3 (3.97) 23.0 (4.46) 22.0 (4.25) 20.9 (3.28)
Work and Social Adjustment Scale
n 55 58 − 3.31 (− 5.84 to − 0.78)
p = 0.01
0.37
Mean (SD) 17.9 (8.41) 15.6 (7.82) 20.7 (9.23) 20.8 (9.64)
Generalised Anxiety Disorder-7 Questionnaire
n 55 56 − 2.96 (− 4.44 to − 1.49)
p < 0.001
0.51
Mean (SD) 6.5 (5.90) 5.1 (4.79) 6.4 (5.66) 8.0 (6.06)
Patient Health Questionnaire-9
n 56 57 − 2.56 (− 4.20 to − 0.93)
p = 0.002
0.40
Mean (SD) 7.2 (6.29) 5.8 (5.58) 6.4 (6.47) 7.9 (6.22)
Hearing Loss Questionnaire-Sound Subscale
n 53 57 − 1.31 (− 0.35 to 2.97)
p = 0.12
0.31
Mean (SD) 25.0 (4.29) 23.2 (5.84) 24.8 (4.14) 24.4 (4.86)
Hearing Loss Questionnaire-Social Subscale
n 56 58 − 2.29 (− 3.47 to − 1.12)
p < 0.001
0.45
Mean (SD) 14.8 (5.21) 13.7 (4.62) 16.2 (4.94) 16.9 (4.58)
Perceived dependency
n 49 55 − 1.66 (− 2.51 to 0.82)
p < 0.001
0.64
Mean (SD) 5.0 (2.61) 3.5 (2.59) 4.6 (2.61) 5.00 (2.47)
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and the cost-effectiveness acceptability curve for the two
scenarios.
When the whole trial period is analysed, the maximum
amount the public sector could contribute towards the
cost of a hearing dog during this period, and remain
value for money, is £442, £503 and £625 at each thresh-
old value respectively. When the active intervention
period is analysed, these figures are £509, £581 and
£726. Finally, when the analysis is repeated using SC-
QALYs, findings are similar (see Table 10, Additional
Table 4 Ordinal regression analyses: clinical severity classifications for the SWEMWBS, WSAS, GAD-7 and PHQ9
n Hearing dog n Wait-list Odds ratioa (95% CI)
p value
Short Warwick-Edinburgh Mental Well-being Scale
Severity Low Medium High Low Medium High
Baseline 55 23 (41.8) 28 (50.9) 4 (8.8) 57 18 (31.6) 34 (59.6) 5
(8.8)
4.20 (1.76 to 10.05)
p < 0.001
T1 55 11 (20.0) 37 (67.3) 7 (12.7) 57 21 (36.8) 36 (63.2) 0
(0.0)











Baseline 55 11(20.0) 24 (43.6) 20 (36.4) 58 5 (8.6) 25 (43.1) 28 (48.3) 0.55 (0.25 to 1.20)
p = 0.133
T1 55 13 (23.6) 26 (47.3) 16 (29.1) 58 8 (13.8) 23 (39.7) 27 (46.6)





Mild Moderate Severe Below cut-off Mild Moderate Severe
Baseline 55 25 (45.5) 14 (25.5) 10 (18.2) 6
(10.9)
56 24 (42.9) 20 (35.7) 4 (7.1) 8
(14.3)
0.33 (0.15 to 0.71)
p = 0.005
T1 55 30 (54.5) 17 (30.9) 4 (7.3) 4
(7.3)














Baseline 56 23 (41.1) 14
(25.0)
12 (21.4) 5 (8.9) 2
(3.6)
57 30 (52.6) 14
(24.6)
4 (7.0) 6 (10.5) 3
(5.3)
0.30 (0.14 to 0.65)
p = 0.002
T1 56 31 (55.4) 13
(23.2)
7 (12.5) 3 (5.4) 2
(3.6)
57 20 (35.1) 16
(28.1)
13 (22.8) 5 (8.8) 3
(5.3)
a This is a proportional odds ratio, thus, for each and every response category c, compares the people who are in categories greater than c with those in
categories less than or equal to c. That is, for a one unit change in the predictor variable, the odds for cases in a category that is greater than c versus less than or
equal to c are k times larger, where k is the odds ratio
Table 5 Cost-effectiveness analysis: descriptive statistics and results
Costing
scenarioa
Trial arm δQALY δCOST ICER Net health benefit (NHB)












QALYs Costs (£) QALYs Costs (£) Obs Coeff Obs Coeff
Multiple imputation analysis for the whole trial period
Excluded 1.300 3909 1.256 4407 165 0.012 165 − 260 Dominant 0.029 0.025 0.021
Included 7123 2954*** 242,912 − 0.185 − 0.136 − 0.086
Multiple imputation analysis for the active intervention period
Excluded 0.372 911 0.353 1206 165 0.014 165 − 291 Dominant 0.034 0.029 0.024
Included 4125 2,954*** 203,959 − 0.182 − 0.133 − 0.084
Key: δ adjusted mean difference, λ opportunity cost threshold, Obs number of observations used to estimate δ, Coeff estimated coefficient 1, ICER incremental
cost-effectiveness ratio
a Refers to two scenarios used for each analysis: costs of providing a hearing dog excluded (i.e. borne by HDfDP charity: the current situation), or included in costs
to public sector (health and social care)
*** p value = 0.01
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file 5; Figure 3, Additional file 6) and conclusions are
unchanged.
Discussion
This is the first RCT to evaluate the impact of a hearing
dog and their cost-effectiveness. Over two thirds of
those invited to participate were recruited and the ran-
domised sample represented the target population.
Compliance to the protocol was good. It represents a
significant step forward in evaluation research on hear-
ing dogs, and within the wider field of assistance dogs
where significant methodological weaknesses in existing
studies has constrained our understanding of the im-
pacts of assistance dogs, including hearing dogs, on peo-
ple’s lives [26].
Adults with hearing loss, particularly those who ac-
quire hearing loss in adulthood, are at risk of a num-
ber of adverse outcomes including social isolation,
mental health difficulties, unemployment, dependence,
increased risk of accidents, poorer physical health and
impaired quality of life [4–9]. Trial findings indicate
that a hearing dog significantly improves recipients’
mental well-being when assessed 6 months post-
receipt of a hearing dog. In addition, receiving a hear-
ing dog significantly improved daily functioning, anx-
iety, depression, fearfulness/social isolation and
perceived dependency on others associated with hear-
ing loss. Effect sizes were small or medium suggesting
at least some hearing dog recipients had experienced
meaningful change in their lives on the domains cap-
tured. Findings from the CACE analysis (SWEMWBS
only) indicate these may be conservative estimates of
effect. The only domain where a statistically signifi-
cant difference was not found was in difficulties
responding to environmental sounds; however, there
was a small effect size favouring HD. Finally, at base-
line, over one third of participants reported poor
mental well-being. At T1, HD participants were four
times more likely to be categorised as having high
mental well-being compared to WL participants.
These findings align with earlier studies (all with one
or more significant study design limitations) which have
evaluated the impact of hearing dogs. Guest’s before and
after study [22] also reported improvements in scores on
standardised measures of mental health and mental
well-being [22]. Previous studies have also reported
fewer difficulties responding to sounds [22], social isola-
tion [22, 24], and fearfulness [22, 24] and a reduced
sense of dependency [24, 25]. In contrast to previous re-
search [21, 25]; however, we also observed significant
improvements in quality of life. Our findings align with
the wider literature on reporting the wide-ranging im-
pacts of assistance dogs on the lives of people with other
sensory or physical impairments [20, 26, 56]. Our
follow-up of some participants at 12 months (to be pub-
lished separately) will provide preliminary evidence on
the extent to which outcomes are maintained, continue
to improve or deteriorate. Data gathered from our
nested qualitative study will also be used to develop an
initial theory of the ‘active ingredients’ of a hearing dog
partnership, the processes by which changes in out-
comes (or not) occur. This work will complement the
trial findings and will usefully inform the design and
scope of future studies.
It is important to note that hearing dog recipients
are individuals who have actively pursued receiving a
hearing dog. Thus findings cannot be applied to all
those with this level of hearing loss. Indeed, it is
likely that some of this population would not consider
such an option due to personal preferences, living
situation or cultural background [57]. In addition,
some of this population have mobility or cognitive
impairments that render them ineligible for such an
intervention.
Our cost-effectiveness analysis implies that, given
the current model of provision in the UK whereby
the costs of hearing dogs are borne by the charitable
sector (HDfDP), this intervention is a worthwhile in-
vestment when seen from a public sector perspective.
Compared to usual care, hearing dogs reduced use
and costs of public sector health and social care ser-
vices, and improved QALY-based outcomes. Whilst it
was not cost-effective for the full cost of hearing dogs
to be borne by the health and social care sector, a
partial contribution by the public sector of between
£442 and £726 (dependent on health opportunity cost
estimate), over the initial 6-month period of the hear-
ing dog partnership could represent value for money
(that is, health benefits would exceed the health op-
portunity costs). If the benefits and impacts on health
observed in this study persisted over the duration of
the hearing dog partnership (11 years on average), a
contribution by the public sector of between £8,236
and £13,538 (calculated using an annual discount rate
of 3.5%; figure dependent on measure of health op-
portunity cost and analysis considered) would repre-
sent value for money. As with other charities
addressing health and social care needs, it would ap-
pear that the NHS and LAs benefit from the service
provided by HDfDP. However, given its dependency
on charitable donation, the extent to which HDfDP
can exceed current rates of provision – and thus fur-
ther benefit the public sector - is unclear.
Finally, we note that the trial evaluated the impacts of
hearing dogs provided by Hearing Dogs for Deaf People.
Assistance Dogs International (ADI) accredited hearing
dog providers in other countries may differ with regard
to training, assessment, matching and support processes.
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Findings may therefore not be applicable to hearing dogs
provided by other ADI accredited organisations or other
types of hearing dog providers.
Limitations
Whilst the trial design and cost-effectiveness methods
used are robust, there are a number of limitations. A
hearing dog partnership typically lasts around 11
years. However, this trial only investigated the first
six months into the partnership. (Pairs where the WL
arm had not received their hearing dogs at twelve
months were also followed up at this time point:
these findings are reported elsewhere.) It is unlikely,
however, that a trial design could be used to investi-
gate longer-term outcomes.
Several HD arm participants did not receive a hearing
dog within the data collection period. Consequently, we
fell short of our target sample size (n = 128) at T1
meaning non-significant findings could be due to a lack
of statistical power, rather than the absence of a true dif-
ference. The study only used self-report measures. Fu-
ture studies could consider independent assessment of
some outcomes (e.g. mental health, social interaction).
The nature of the intervention, and the way it is pro-
vided, inherently introduce limitations that are not pos-
sible to remediate. Individuals in the WL arm had
already been accepted for a hearing dog and had under-
gone HDfDP’s assessment process, thus they were not a
true ‘no intervention’ comparator. However, we note
that any impacts of this appear negligible (see Table 2).
In addition, whilst study participants were blinded to
which arm of the study they were in, it was not possible
to blind them regarding whether they had received the
intervention (a hearing dog) or not. Finally, this trial did
not seek to compare receiving a hearing dog with pet
dog ownership. Where study participants had previous
experience of a pet dog, the qualitative element of this
study (to be published separately) explored views on the
differences between the two. Research, incorporating a
comparative design, which sought to understand and
measure the ‘added value’ of an assistance dog over a pet
dog would be a useful addition to the growing evidence
base on assistance dogs.
In taking a health and social care perspective to our
cost-effectiveness evaluation, this study did not include
the impact of hearing dogs on recipients’ productivity,
nor the benefits and costs of informal care, nor the ben-
efits and costs on family members or HDfDP volunteers
involved in hearing dog training. If a broader perspective
was adopted, these could be considered [58]. As a char-
ity, HDfDP draws on charitable funding and volunteers’
input. If the budget and resource from charitable donors
and volunteers were also considered, it becomes more
complex to assess the opportunity cost (i.e. the benefits
foregone) of investing in this intervention. To our know-
ledge, few full economic evaluations of charity-funded
interventions have been undertaken and no method
guidance has explicitly considered the opportunity cost
implications arising from costs falling on charitable
budgets.
To aid interpretation of cost-effectiveness results, we
used an estimate of health opportunity costs (sometimes
referred to as a cost-effectiveness threshold). This re-
flects how much benefit could be derived from alterna-
tive use of resources. At present, however, there is no
empirical threshold value available for the health and so-
cial care sector combined. In the absence of this, we
drew on widely used estimates of the health opportunity
cost for the health care sector, which may not be repre-
sentative of the social care sector. Finally, we note our
estimates of the potential public sector contribution are
subject to structural uncertainty because they assume ef-
fects on health observed during the trial period persist
for the entire period of the hearing dog partnership.
Whether this is the case is yet to be established.
Conclusions
Findings indicate that, hearing dogs (provided by an or-
ganisation adhering to ADI standards) positively impact
recipients’ mental well-being as well as daily functioning,
mental health, experiences of fearfulness and social iso-
lation and perceived dependency on others, at least in
the short term. They suggest that hearing dogs are good
value for money for the public sector but only if it does
not bear the full cost of providing them. The study is an
example of successful delivery of a trial in a third sector
organisation with no previous experience of integrating
a trial into its application, assessment and delivery pro-
cesses. It also breaks new ground within the wider field
of assistance dog evaluations.
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